Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient (API) supporting its proprietary ONC010 drug candidate. The batch, produced through Dalton Pharma Services’ Process Optimization and Intermediate Scale-Up Program, achieved approximately 99.3% purity with no detectable residual solvents following comprehensive quality control and Certificate of Analysis review. This milestone marks a significant step forward for the company’s PNKP inhibitor program, as it demonstrates the reproducibility and scalability of the manufacturing process.
The scale-up campaign is expected to support future analytical qualification, formulation development, engineering batch production, and Good Manufacturing Practice (GMP) manufacturing activities ahead of planned First-in-Human studies. According to the company, the successful batch validates the manufacturing process and positions Onco-Innovations to advance its oncology pipeline. The ONC010 program targets solid tumors through patented technology, for which the company holds an exclusive worldwide license.
In addition to the manufacturing progress, Onco-Innovations announced the appointment of Dave Antony as chief financial officer and corporate secretary, effective immediately, succeeding Nico Mah. This leadership change comes as the company prepares for the next phases of drug development.
The implications of this milestone are significant for the biotechnology industry and for patients with solid tumors. By achieving high-purity API at a 300-gram scale, Onco-Innovations demonstrates that its manufacturing process is robust and scalable, which is critical for advancing to clinical trials. The ability to produce consistent, high-quality API is a prerequisite for regulatory filings and eventual commercialization. For investors, this news signals that the company is moving closer to clinical-stage development, potentially de-risking the program. For the broader oncology field, the PNKP inhibitor approach offers a novel mechanism to target DNA repair in cancer cells, which could lead to new treatment options.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. For more information, visit the company’s newsroom at https://ibn.fm/ONNVF.
